TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06215703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Playing Task
Description: For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
Study: NCT04538378

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT chest, abdomen and pelvis
Description: Screening and baseline and every 8 (+/-1) weeks after start of therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI chest, abdomen and pelvis
Description: Screening and baseline and every 8 (+/-1) weeks after start of therapy.
Study: NCT04793646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine syrup
Description: N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Placebo syrup 15 mL twice a day for 3 months
Study: NCT05974579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-AP-101
Description: At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-AP-101
Description: At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated.
Study: NCT05699915

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiology consultation
Description: * Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio \> 15 and left atrial (LA) area \> 30 cm2.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest Computed Tomography (CT) without contrast
Description: Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-invasive endothelial function tests
Description: * FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiogram
Description: An ECG will be taken prior to each ICI cycle during the first three months of treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Extra serum sample (7.5 mL)
Description: An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
Study: NCT06215703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Playing Task
Description: For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Playing Task
Description: For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Playing Task
Description: For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
Study: NCT04892173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90301900 (NBTXR3)
Description: Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Solution for infusion
Study: NCT05671718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led Treatment in Primary Care
Description: At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
Study: NCT06562660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apnoeic
Description: In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
Study: NCT04892173

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
Study: NCT06204900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Cuff and Retractor System
Description: Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
Study: NCT04655755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study: NCT05717530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound site local anesthesic infiltration
Description: : at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
Study: NCT05989022

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Injection of contrast enhancing agent Gadovist for MRI investigation
Description: Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Injection of contrast enhancing agent Imeron for B-CT investigation
Description: Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
Study: NCT05937308

Intervention type: DEVICE
Group type: OTHER
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study: NCT05211323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT06462521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare Piecemeal Resection (CSPR)
Description: Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare Endoscopic Mucosal Resection (Cold EMR)
Description: Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
Study: NCT04199871

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: dichoptic 3D movies
Description: dichoptic movies presented on a Nintendo 3DS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dichoptic 3D movies
Description: dichoptic movies presented on a Nintendo 3DS
Study: NCT05829343

Intervention type: PROCEDURE
Intervention: Laparoscopic Left colectomy
Description: Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.

Intervention type: PROCEDURE
Intervention: Robotic left colectomy
Description: Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
Study: NCT05626634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352, bexicaserin
Description: LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Study: NCT04655755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05486572

Intervention type: OTHER
Group type: OTHER
Intervention: Abbreviated Magnetic Resonance Imaging with serum AFP
Description: Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Ultrasound Screening with serum AFP
Description: abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
Study: NCT04964986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study: NCT06146751

Intervention type: DRUG
Intervention: Superparamagnetic Iron Oxide Nanoparticles
Description: Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
Study: NCT06393517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Study: NCT05197400

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: preoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: preoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: postoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: postoperative airway ultrasonography
Description: Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness
Study: NCT06473779

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: IMP. Subcutaneous injection. Unit dose strengths 210 mg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: IMP. Subcutaneous injection. Unit dose strengths 210 mg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: IMP. Subcutaneous injection. Unit dose strengths 210 mg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (AIRSUPRA®)
Description: AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (AIRSUPRA®)
Description: AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol/budesonide (AIRSUPRA®)
Description: AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
Study: NCT05480098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Topical
Description: Topical brimonidine intraoperatively for hemostasis
Study: NCT06584292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block
Description: Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
Study: NCT06296927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
Study: NCT05302063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Description: Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
Study: NCT06349889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT
Study: NCT06492616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Administered as oral tablets
Study: NCT05818553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-562
Description: Once daily oral or G-tube treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-562
Description: Once daily oral or G-tube treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-562
Description: Once daily oral or G-tube treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-562
Description: Once daily oral or G-tube treatment.
Study: NCT05848947

Intervention type: DRUG
Group type: OTHER
Intervention: 99mTc-Macro Albumin Aggregate
Description: Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
Study: NCT04679935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection